CBD trials in canine epilepsy and arthritis
CBD has been studied as an additional treatment in dogs with difficult-to-control epilepsy and osteoarthritis. A 2019 epilepsy trial found fewer seizures in the CBD group, while a 2018 arthritis trial reported improvements in pain and activity. Both also recorded changes in liver-enzyme measurements.
The epilepsy trial showed a partial signal
A 2019 randomised blinded trial enrolled 26 dogs with intractable idiopathic epilepsy. CBD or placebo was added to their existing antiepileptic treatment. After withdrawals and other exclusions, the analysis included nine dogs in the CBD group and seven receiving placebo.
The CBD group had a median 33% reduction in seizure frequency. However, the proportion reaching the trial’s responder threshold—a reduction of at least 50%—was similar between groups. Two CBD-treated dogs developed ataxia and were withdrawn, and alkaline phosphatase activity increased in the CBD group. The result is therefore more specific than saying that CBD treated epilepsy successfully.
A joint-pain study asked a different question
Gamble and colleagues’2018 crossover study had 16 dogs complete treatment periods for osteoarthritis. Pain and activity scores improved during the CBD condition. Some dogs also showed increased alkaline phosphatase activity.
An improvement in pain or activity is a symptom-related result, not evidence that damaged cartilage regrew. A change in an enzyme measure is also not, by itself, a complete diagnosis of liver injury. These distinctions make the findings useful: they identify both a possible benefit and observations that require interpretation within veterinary care.
Add-on treatment is not replacement treatment
The epilepsy study retained conventional antiepileptic treatment. Its design therefore tested an additional intervention, not the removal of established medicines. Recasting an add-on result as permission to substitute a pet product would change the clinical question that was investigated.
Preparation also matters. The words hemp, CBD and cannabis do not describe identical compositions. A pet-labelled product, a human medicine and a research preparation may differ in ingredients and quality controls. A trial result belongs to its intervention and cannot be transferred simply because another label mentions the same plant.
Adverse exposure needs veterinary attention
The US FDA states that it has not approved cannabis for use in animals; this describes US regulatory status. Its veterinary information lists lethargy, heavy drooling, vomiting, agitation, tremors and convulsions among possible signs after cannabis ingestion. Suspected adverse exposure warrants prompt veterinary attention.
Sources & further reading
General information, not individual legal or medical advice.